Osteoporosis
Effects of endocrine-disrupting chemicals extend to obesity, osteoporosis, IQ and beyond
Top stories in endocrinology: Phthalates impact testosterone levels, bigger arm muscles reduce osteoporosis risk
Frailty plus trabecular bone score fails to improve fracture risk prediction
Men with bigger arm muscles have lower osteoporosis risk
Zoledronate infusion preserves BMD gains after denosumab discontinuation for women with osteoporosis
Postmenopausal women with osteoporosis who received a single infusion of zoledronate after 2 to 5 years of denosumab therapy retained more than half of bone mineral density gained before stopping treatment with no increase in vertebral fractures, according to findings published in the Journal of Bone and Mineral Research.
Pheochromocytoma, paraganglioma underrecognized cause of secondary osteoporosis
Recent fracture ‘addressable risk factor’ for new fracture
Polygenic disease may explain increased bone fragility among children without osteogenesis imperfecta
A cohort of children presenting with increased bone fragility and no extraskeletal signs of osteogenesis imperfecta tended to have a collection of common gene variants that predispose to osteoporotic fracture rather than a monogenic etiology of their condition, according to findings published in the Journal of Bone and Mineral Research.
Delays between denosumab injections may worsen BMD response
A longer interval between denosumab injections is associated with suboptimal bone mineral density response at the spine and total hip, and strategies to improve the timely administration of denosumab in real-world settings are needed, according to findings published in The Journal of Clinical Endocrinology & Metabolism.